一种基于重组体的微型疫苗通过鼻内免疫来对抗新冠病毒感染。
A micro-sized vaccine based on recombinant fights against SARS-CoV-2 infection intranasal immunization.
作者信息
Li Letian, Hao Jiayi, Jiang Yuhang, Hao Pengfei, Gao Yuwei, Chen Jing, Zhang Guoqing, Jin Ningyi, Wang Maopeng, Li Chang
机构信息
Research Unit of Key Technologies for Prevention and Control of Virus Zoonoses, Chinese Academy of Medical Sciences, Changchun Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Changchun 130122, China.
Wenzhou Key Laboratory for Virology and Immunology, Institute of Virology, Wenzhou University, Wenzhou 325035, China.
出版信息
Acta Pharm Sin B. 2023 Feb 23;13(7):3168-76. doi: 10.1016/j.apsb.2023.01.005.
COVID-19 has globally spread to burden the medical system. Even with a massive vaccination, a mucosal vaccine offering more comprehensive and convenient protection is imminent. Here, a micro-sized vaccine based on recombinant (rLP) displaying spike or receptor-binding domain (RBD) was characterized as microparticles, and its safety and protective effects against SARS-CoV-2 were evaluated. We found a 66.7% mortality reduction and 100% protection with rLP against SARS-CoV-2 in a mouse model. The histological analysis showed decreased hemorrhage symptoms and increased leukocyte infiltration in the lung. Especially, rLP:RBD significantly decreased pulmonary viral loads. For the first time, our study provides a -vectored vaccine to prevent COVID-19 progress and transmission intranasal vaccination.
新冠病毒已在全球传播，给医疗系统带来负担。即便进行了大规模疫苗接种，一种能提供更全面便捷保护的黏膜疫苗也即将问世。在此，一种基于展示刺突蛋白或受体结合域（RBD）的重组（rLP）的微型疫苗被表征为微粒，并评估了其对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的安全性和保护效果。我们发现在小鼠模型中，rLP对SARS-CoV-2有66.7%的死亡率降低和100%的保护作用。组织学分析显示肺部出血症状减轻，白细胞浸润增加。特别是，rLP:RBD显著降低了肺部病毒载量。我们的研究首次提供了一种通过鼻内接种来预防新冠病毒进展和传播的载体疫苗。
Zotero 插件